clopidogrel (Plavix)

Subscribe to Selected New Research on clopidogrel

1499 relevant articles (164 outcomes, 389 trials/studies) found for this Drug

Description: RN given refers to cpd without isomeric designation

Also Known As:

Plavix; Iscover; PCR 4099; PCR-4099; SC 25989C; SC 25990C; SR 25989; clopidogrel bisulfate; clopidogrel, (+)(S)-isomer; methyl 2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno(3,2-c)pyridin-5-yl)acetate hydrochloride, hydrate

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Thiophenes: 10

Ticlopidine: 887

clopidogrel: 1499

Experts

1.	Cannon, Christopher P: 15 articles (09/2008 - 10/2002)
2.	Bhatt, Deepak L: 12 articles (10/2008 - 05/2002)
3.	Yusuf, Salim: 11 articles (09/2008 - 09/2002)
4.	Sabatine, Marc S: 11 articles (04/2008 - 02/2005)
5.	Murphy, Sabina A: 9 articles (05/2008 - 09/2005)
6.	Gibson, C Michael: 9 articles (04/2008 - 02/2005)
7.	Braunwald, Eugene: 8 articles (01/2008 - 03/2005)
8.	Fox, Keith A A: 8 articles (01/2008 - 09/2002)
9.	McCabe, Carolyn H: 8 articles (12/2007 - 02/2005)
10.	Montalescot, Gilles: 8 articles (12/2007 - 01/2004)

Related Diseases

1.	Stroke (Strokes) 09/14/2005 - "Overall, pretreatment with clopidogrel resulted in a highly significant reduction in cardiovascular death, MI, or stroke from randomization through 30 days (70 [7.5%] vs 112 [12.0%]; adjusted OR, 0.59 [95% CI, 0.43-0.81]; P = .001; number needed to treat = 23)" 01/01/2003 - "The MATCH trial is currently being conducted to test the hypothesis that long-term administration of clopidogrel on top of ASA is superior to clopidogrel alone for the reduction of major ischaemic events in patients with recent TIA or ischaemic stroke who are at high risk of atherothrombotic recurrence" 07/01/2006 - "Clopidogrel has not shown significant reduction in reoccurrence of stroke and has not been studied for patients with a previous TIA" 11/01/2006 - "A prediction model which allows to identify patients in whom clopidogrel or dipyridamol plus ASA is superior to ASA for the secondary prevention of stroke is presented." 05/01/2005 - "A prediction model is presented which allows the identification of patients in whom clopidogrel is superior to ASA for the secondary prevention of stroke" Get all the results and reference details, order at left...
2.	Myocardial Infarction 07/04/2006 - "Clopidogrel was also associated with a significant reduction in the odds of an in-hospital death or myocardial infarction in patients who achieved partial (OR 0.30, p = 0.003) or complete STRes at 90 min (OR 0.49, p = 0.056), whereas clinical benefit was not apparent in patients who had no STRes (OR 0.98, p = 0.95) (p for interaction = 0.027)" 01/01/2006 - "After ACS with non-ST-elevation myocardial infarction the combined therapy with ASA and clopidogrel gives a better outcome than ASA alone" 09/14/2005 - "OBJECTIVE: To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events" 01/01/2006 - "Efficacy of clopidogrel in acute myocardial infarction (AMI) was studied only in two trials" 04/15/2008 - "METHODS AND RESULTS: We measured ST2 at baseline in 1239 patients with ST-elevation myocardial infarction from the CLopidogrel as Adjunctive ReperfusIon TherapY-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28) trial" Get all the results and reference details, order at left...
3.	Acute Coronary Syndrome 01/01/2006 - "CONCLUSIONS: Clopidogrel given for up to 1 year in patients undergoing PCI after presentation with acute coronary syndromes is a highly cost-effective treatment strategy." 08/01/2003 - "Thienopyridines such as clopidogrel have been shown to provide significant benefits in the management of acute coronary syndromes (ACS), either as an alternative to or in combination with ASA therapy" 06/01/2006 - "Clopidogrel for up to one year after PCI is cost-effective for people with acute coronary syndromes." 01/01/2007 - "Reviewing the results from trials completed to date that have assessed clopidogrel in patients with acute coronary syndromes may help to answer some of these questions" 01/01/2007 - "Clopidogrel has demonstrated improved outcomes for patients with acute coronary syndromes in several large randomized controlled trials" Get all the results and reference details, order at left...
4.	Thrombosis (Thrombus) 04/01/2005 - "Because of its central role in the formation and stabilization of a thrombus, the P2Y (12) receptor is a well-established target of antithrombotic drugs such as clopidogrel, which has proven efficacy in many clinical trials and experimental models of thrombosis" 11/01/1995 - "Clopidogrel may be beneficial in the prevention of arterial thrombosis." 11/22/2006 - "Clopidogrel is essential for protection against thrombosis in areas where the endothelium is not intact" 01/29/2008 - "METHODS AND RESULTS: We performed a prospective, multicenter, randomized, placebo-controlled trial evaluating the pharmacodynamics of clopidogrel in children (0 to 24 months) with a cardiac condition at risk for arterial thrombosis" 01/01/2007 - "Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study." Get all the results and reference details, order at left...
5.	Hemorrhage 03/01/2007 - "Lack of nonresponse and profound inhibition with clopidogrel allow for the maintenance of a delicate balance between proven efficacy and acceptable bleeding risks for long-term secondary prevention in outpatients after acute vascular events." 02/15/2005 - "The durable efficacy of clopidogrel relative to the risk for hemorrhage should be further explored before more protracted therapy can be recommended." 08/01/2008 - "Although many studies in the cardiothoracic literature exist about the relationship between clopidogrel and postoperative bleeding, there is scarce data in the general surgery literature" 03/01/2008 - "Studies were included if they met the following criteria: randomized controlled trials, prospective observational trials, or retrospective trials; characteristics and outcomes of patients who were exposed to clopidogrel within 7 days before CABG were analyzed; at least 20 patients were enrolled; and reported outcomes were related to transfusion requirements, resource utilization, clinical events, or hemorrhage-related reoperation rates" 12/01/2007 - "The Prague-8 Study evaluated whether routine clopidogrel administered >6 h pre-angiography would be a safe way to achieve therapeutic drug levels in case a follow-up intervention would be considered immediately, but appeared not justified because of bleeding complications" Get all the results and reference details, order at left...
211 Diseases and 1499 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	Ticlopidine (Ticlid)
3.	Dipyridamole (Persantine)
4.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
5.	Warfarin (Coumadin)
6.	clopidogrel (Plavix)
7.	prasugrel
8.	Heparin (Liquaemin)
9.	Glycoproteins (Glycoprotein)
10.	abciximab (ReoPro)
404 Drugs and Important Bio-Agents and 1056 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Stents
2.	Transplants (Transplant)
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Drug-Eluting Stents
5.	Angioplasty (Angioplasties)
44 Therapies and Procedures and 361 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>